Precise Bio

Precise Bio is a regenerative medicine company founded in 2015 by Aryeh Batt, Shay Soker, and Dr. Anthony Atala, all of whom bring extensive experience to the venture. Aryeh Batt, the CEO, developed the company's core printing technology and has over two decades of executive experience in product development and R&D at firms like Orbotech. Dr. Atala, the Chief Medical Officer, is the director of the Wake Forest Institute of Regenerative Medicine (WFIRM) and a globally recognized leader in the field. Chief Scientific Officer Shay Soker is also a professor at WFIRM and an expert in cell biology and tissue engineering. Their collective expertise forms the foundation of the company, which originated from the synergy between Batt's revolutionary printing technology and the regenerative medicine research at WFIRM.

The company operates at the intersection of biotechnology and 3D printing, developing a proprietary 4D bio-fabrication platform. This technology is designed to print functional tissues and complex organs using a patient's own cells, aiming to resolve significant challenges in organ transplantation and regenerative medicine. Unlike conventional bio-printing, Precise Bio's platform achieves single-cell resolution and spatial accuracy, enabling the construction of tissues with structural integrity and long-term cell viability. The business model is centered on developing and commercializing these bio-printed products for various medical fields, including ophthalmology, cardiology, orthopedics, and dermatology.

Precise Bio's initial focus is on ophthalmology, with a dedicated business unit established to advance this pipeline. Key products in development include two cornea products and a retinal implant for age-related macular degeneration. The company has demonstrated successful results in animal models, including being the first to transplant a 3D-printed cornea graft in an animal. This progress is supported by strategic collaborations, notably with Carl Zeiss Meditec, which is also an investor. The company operates from facilities in Winston-Salem, North Carolina, and Modi'in, Israel, positioning itself to transition from R&D to clinical development. Since its inception, Precise Bio has secured a total of $12 million in funding over four rounds, including a Series B in January 2024, to finance its ongoing development and operational expansion.

Keywords: 4D bio-fabrication, regenerative medicine, tissue engineering, organ transplantation, bio-printing, ophthalmology, cornea transplant, retinal implant, cell therapy, bio-ink, Aryeh Batt, Shay Soker, Anthony Atala, Wake Forest Institute for Regenerative Medicine, Carl Zeiss Meditec, organoids, bio-printed organs, single-cell resolution printing, personalized medicine, tissue regeneration, medical devices, life sciences, healthcare technology, biomaterials